Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

This study is testing a combination of three drugs — zanzalintinib (XL-092), durvalumab, and tremelimumab — as a first-line treatment for liver cancer (hepatocellular carcinoma) that cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with inoperable hepatocellular carcinoma (liver cancer) - You have not yet received any systemic (whole-body) treatment for this cancer - You are 18 years or older with a good performance level - Your organs are functioning well enough to safely receive treatment **You may NOT be eligible if...** - You have previously received systemic therapy for liver cancer - You have significant organ dysfunction - You have active autoimmune disease or are on long-term immunosuppressive therapy - You have had prior serious side effects from similar immunotherapy drugs Talk to your doctor to see if this trial is right for you.